Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback